Pharmafile Logo

Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and initial communications platforms. In an earlier quantitative wave of research we had identified four segments to define physician treatment and prescription behaviors. Our next challenge was to validate the segmentation. Our client wanted to gain a deeper qualitative market understanding of treatment views and prescribing motivators of the four segments. They also needed to open lines of communications within the team, giving both local and remote team members the opportunity to engage and interact with the research and segmentation.

Read the full case study: https://www.researchpartnership.com/news/2017/09/qualitative-segmentation-validation-study-with-back…

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

From activity to impact: 5 takeaways from MAPS Americas 2026

Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercializationâ„¢. Now we’re back in the…

Precision Medical Affairs in Action: Using AI and Analytics to Elevate Strategy, Engagement, and Impact

Discover how AI, analytics and real-world data are reshaping Medical Affairs.

How did multifaceted support from across Inizio help a biotech firm prepare for launch?

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.